HER2-Negative Breast Cancer Market to See Hike in Incident Cases in 5EU, States GlobalData in Discounted Report Published at MarketPublishers.com31 Oct 2016 • by Natalie Aster
LONDON – Breast cancer is the 2nd most prevailing type of cancer globally and the most widespread cancer affecting women across the world. All in all, breast cancer 5-year survival rates are comparatively high, at close to 90%, but this pertains to the stage and subtype of the disease.
More than that, the novel drugs that will likely be entering the market are poised to command a high price in manifold settings, and there will be a constant upsurge in the incident rates of HER2-negative breast cancer (1.8% AGR) in the foreseeable future. However, in comparison with other countries across the 5EU, Germany’s market is anticipated to expand at a more sluggish pace; the country’s share of the overall market is projected to decrease to 8% by 2023.
Discounted research report “HER2-Negative Breast Cancer - 5EU Drug Forecast and Market Analysis to 2023” drawn up by GlobalData delves deep into the HER2-negative breast cancer marketplace. It presents comprehensive segmentation of the HER2 negative breast cancer sector into 2 key subtypes. The report gives a review on the disease covering etiology, epidemiology, diagnosis, symptoms, pathology and treatment modalities; includes a comprehensive overview of the competitive landscape. The study provides details about the major drugs in 5EU comprising product description, efficacy and safety profiles and also a granular SWOT assessment. The study sheds light on the current therapeutic landscape, burning unmet needs, present-day pipeline, and manifold commercial opportunities emerging in the regional HER2-negative breast cancer marketplace, with in-depth coverage of numerous settings. It includes a comprehensive examination of the impact of major events in tandem with the driving forces and restraints impacting the 5EU HER2-negative breast cancer market. Furthermore, the report covers detailed sales forecasts for the major drugs in 5EU are provided through to 2023.
More discounted and new research reports by the publisher can be found at GlobalData page.